Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin

Clinical Pharmacology and Therapeutics

Volumn 70, Issue 6, 2001, Pages 546-551

  Mulder, André B ^b   Van Lijf, Hans J ^b   Bon, Michelle A M ^b   Van Den Bergh, Frank A J T M ^b   Touw, Daan J ^b   Neef, Cees ^b   Vermes, István ^a  

^a MEDISCH SPECTRUM TWENTE   (Netherlands)

^b Clinical Pharmaceutical and Toxicological Laboratory   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CYTOCHROME P450 2D6; DEXTROMETHORPHAN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SIDE EFFECT;

ADULT; AGED; ANTICHOLESTEREMIC AGENTS; CYTOCHROME P-450 CYP2D6; DNA; FEMALE; GENOTYPE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PHENOTYPE; POLYMORPHISM, GENETIC; SIMVASTATIN;

EID: 0035657076     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2001.120251     Document Type: Article

References (21)

1. Coronary artery disease regression: Convincing evidence for the benefit of aggressive lipoprotein management
2. Lipid lowering, regression, and coronary events: A review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council meeting
3. Regulation of the mevalonate pathway
4. Clinical pharmacokinetics and practical applications of simvastatin
5. In vitro comparative inhibition profiles of major drug metabolising cytochrome P450 isoenzymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors
6. Nomenclature for human CYP2D6 alleles
7. Molecular mechanisms of genetic polymorphisms of drug metabolism
8. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences
9. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution
10. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine
11. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population
12. Is the cholesterol-lowering effect of simvastatin influenced by CYP2D6 polymorphism?
13. Detection of debrisoquine hydroxylation phenotypes
14. Cytochrome P450 enzyme system: Genetic polymorphisms and impact on clinical pharmacology
15. PCR-based genotyping for duplicated and deleted CYP2D6 genes
16. Genetic mechanism for duplication and multiplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes
17. High-performance liquid chromatography determination of dextromethorphan and dextrorphan for oxidation phenotyping by fluorescence and ultraviolet detection
18. Pharmacogenetics of dextromethorphan O-demethylation in man
19. Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation
20. Confidence interval analysis microcomputer program
21. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population